Post‐ FDA Approval Experience With Momelotinib in JAK Inhibitor‐Naïve Myelofibrosis: Focus on Anemia Response and Treatment‐Emergent Nephropathy and Peripheral Neuropathy

American Journal of Hematology 2026 Open access

Read full text
Authors: Ayalew Tefferi, Maymona Abdelmagid, Jeanne Palmer, Aref Al‐Kali, Cecilia Y. Arana Yi, Aasiya Matin, Hassan B. Alkhateeb, Talha Badar, Yassin Bashir, Kaaren K. Reichard, Rong He, Animesh Pardanani
+1 more Naseema Gangat
DOI: 10.1002/ajh.70203
Cited by: 6
References: 16

Abstract

Real-world experience using momelotinib as first-line JAK2 inhibitor therapy in myelofibrosis. Anemia response was moderate (23%) while treatment-emergent adverse events included nephropathy (29%) and peripheral neuropathy (20%).

Fields of Study & Subjects

Myeloproliferative Neoplasms: Diagnosis and Treatment Vasculitis and related conditions Chronic Myeloid Leukemia Treatments

Publication details

Journal / source
American Journal of Hematology
Publisher
Wiley
Volume
101
Issue
3
Pages
570–576
Publication date
8 January 2026
Language
EN